Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Fig. 6

Emab inhibits the activation CD27–CD10–IgD– (DN) B cells in response to TLR7 stimulation. CD10–CD27–IgD+ (naïve) and CD10–CD27–IgD– (DN memory) B-cell subsets were sorted and left untreated or stimulated with R848, anti-human F(ab′)2 IgM, or a combination of R848 plus anti-IgM in the presence of Emab or isotype control Ab. Cells were cultured for 5 days and then cell viability and surface expression of CD38 and CD27 and cell frequencies of live cells were analyzed by flow cytometry. a Flow data show results from one representative experiment. Gates depict the frequencies of CD27hiCD38hi (activated) cells in each subset (b, c) Cumulative data from five experiments using tonsils from different donors showing the percentage of CD27hiCD38hi of gated live cells (b) or the frequencies of live cells in culture (c). Tonsils used in these experiments were preanalyzed and selected to contain >10% CD95+IgD– or CD27–CD10– cells. ***p < 0.001, as determined by two-way ANOVA with Bonferroni post test. Emab epratuzumab

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us